Login to Your Account



Clinic Roundup


Friday, July 15, 2011
Inovio Pharmaceuticals Inc., of Blue Bell, Pa., said that in a Phase I trial, its product VGX-3400X, a DNA vaccine, generated significant T-cell and antibody responses against avian H5N1 delivered with intramuscular electroporation.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription